Skip to main
VKTX

Viking Therapeutics (VKTX) Stock Forecast & Price Target

Viking Therapeutics (VKTX) Analyst Ratings

Based on 8 analyst ratings
Strong Buy
Strong Buy 63%
Buy 38%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Viking Therapeutics is a healthcare service provider with a promising clinical program pipeline, which includes three products with significant potential for treating metabolic and endocrine disorders. The company has a strong partnership in place with Ligand Pharmaceuticals and has taken meaningful steps to advance its VK2809 program. Despite facing standard industry risks, Viking Therapeutics shows potential for successful clinical outcomes and an attractive valuation for investors.

Bears say

Viking Therapeutics is a healthcare service provider focusing on metabolic and endocrine disorders, with a pipeline primarily composed of VK2809, VK5211, and VK0214 products. Despite positive data for VK2809 and VK0214, the absence of a plateau in the clinical trial for VK5211 could indicate potential upside for the company's phase III VANQUISH doses. The transition to an auto-injector for VK2735 shows confidence in its potential, but there is still a risk that VK2735 may not replicate the weight loss and tolerability in Phase 3 trials as seen in Phase 2 trials.

Viking Therapeutics (VKTX) has been analyzed by 8 analysts, with a consensus rating of Strong Buy. 63% of analysts recommend a Strong Buy, 38% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Viking Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Viking Therapeutics (VKTX) Forecast

Analysts have given Viking Therapeutics (VKTX) a Strong Buy based on their latest research and market trends.

According to 8 analysts, Viking Therapeutics (VKTX) has a Strong Buy consensus rating as of Sep 27, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $98, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $98, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Viking Therapeutics (VKTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.